Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.62 |
| ▸ | CASP3 | P42574 | 3/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741824 | 0.85 | NPC1 (0.67) | LMNATHRBS1PR1S1PR3NPC1 | |
| SCHEMBL5387968 | 0.81 | S1PR1 (0.54) | LMNATHRBS1PR1S1PR3NPC1 | |
| SCHEMBL3456771 | 0.80 | NPC1 (0.66) | LMNATHRBCASP3NPC1RAB9A | |
| SCHEMBL35210436 | 0.80 | ALDH5A1 (0.52) | LMNAS1PR1NPC1RAB9ATP53 | |
| SCHEMBL29147406 | 0.80 | LMNA (0.70) | LMNATHRBS1PR1CASP3S1PR3 | |
| SCHEMBL19030812 | 0.80 | HDAC4 (0.57) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL26093825 | 0.80 | LMNA (0.70) | LMNATHRBS1PR1CASP3S1PR3 | |
| SCHEMBL4787889 | 0.80 | S1PR1 (0.57) | LMNATHRBS1PR1S1PR3NPC1 | |
| SCHEMBL5208706 | 0.79 | LMNA (0.65) | LMNATHRBS1PR1CASP3S1PR3 | |
| SCHEMBL5205641 | 0.79 | LMNA (0.65) | LMNATHRBS1PR1CASP3S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549640-A4 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7223791-B2 | Function regulator for retinoid relative receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040157881-A1 | Function regulator for retinoid relative receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1405636-A1 | FUNCTION REGULATOR FOR RETINOID RELATIVE RECEPTOR | Takeda Chemical Industries, Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157881-A1 | Function regulator for retinoid relative receptor | RXRA, RARA, RARG | LMNA 3786/4885THRB 129/4885S1PR1 1456/4885 |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | EDNRA, OXGR1, EDNRB | LMNA 4831/4885THRB 1297/4885S1PR1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.